- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Dermatologists should be on front lines if bio-terrorism occurs
Should a biological attack reach American soil, dermatologists must positionthemselves on the front lines, according to Michael J. Franzblau, M.D.,clinical professor of dermatology at the University of California at SanFrancisco's School of Medicine, and a respected researcher and speaker onbio-terrorism.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Road to RAD: Taking Itch Into Consideration
Derm Dispatch: Melanoma Doesn’t Wait—Neither Should You
Road to RAD: Lebrikizumab for AD
Road to RAD: Nemolizumab for AD
Expert Insights Highlight Novel ITK Inhibition With Soquelitinib for AD
Weighing In on Biologics and JAK Inhibitors for Atopic Dermatitis
What to Know When Targeting IL-13 vs IL-31 in Atopic Dermatitis
LEVEL UP Trial Sets New Benchmark for Atopic Dermatitis Treatment
How OX40-Targeted Therapies Might Reshape Biologic Strategy in AD
Expanding Topical Non-Steroidal Options in Atopic Dermatitis to Reduce Chronic Steroid Use
Related Content
